{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T06:06:46Z","timestamp":1789625206147,"version":"build-2803163510"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Objectives<\/jats:title>\n                <jats:p>To compare work absenteeism and short-term disability among adults with psoriasis or psoriatic arthritis (PsA), versus controls in the USA. <\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Adults eligible for work absenteeism and\/or short-term disability benefits between 1\/1\/2009 and 4\/30\/2020 were screened in the IBM\u00ae MarketScan\u00ae Commercial and Health and Productivity Management Databases. The following groups were defined: (1) psoriasis:\u2009\u2265\u20092 psoriasis diagnoses\u2009\u2265\u200930\u00a0days apart and no PsA diagnoses; (2) PsA:\u2009\u2265\u20092 PsA diagnoses\u2009\u2265\u200930\u00a0days apart; (3) control: absence of psoriasis and PsA diagnoses. Controls were matched to psoriasis and PsA patients based on age, gender, index year, and comorbidities. Non-recreational work absences and sick leaves were evaluated in absentee-eligible patients, and short-term disability was evaluated in short-term disability-eligible patients. Costs (in 2019 USD) associated with each type of work absence were evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>4261 psoriasis and 616 PsA absentee-eligible and 25,213 psoriasis and 3480 PsA short-term disability-eligible patients were matched to controls. Average non-recreational work absence costs were $1681, $1657, and $1217 for the PsA, psoriasis, and control group, respectively. Compared with psoriasis patients and controls, more PsA patients had sick leaves after 1\u00a0year (56.2% versus 55.6% and 41.5%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Similarly, short-term disability was more frequent in PsA patients than psoriasis patients and controls at year one (8.8% versus 5.6% and 4.7%, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001) and corresponding costs were higher ($605, $406, and $335 on average, <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Annual work absenteeism and short-term disability were consistently greater among patients with PsA and psoriasis than controls, highlighting the substantial economic burden of psoriatic disease.<\/jats:p>\n                <jats:p><jats:table-wrap><jats:table><jats:tbody>\n                      <jats:tr>\n                        <jats:td colspan=\"2\"><jats:bold>Key points<\/jats:bold><jats:italic>\u2022 Patients with PsA had greater short-term disability compared with patients with psoriasis and patients with neither psoriasis nor PsA.<\/jats:italic><jats:italic>\u2022 Patients with PsA and patients with psoriasis incurred greater non-recreational work absences and sick leaves than patients with neither psoriasis nor PsA.<\/jats:italic><\/jats:td>\n                      <\/jats:tr>\n                    <\/jats:tbody><\/jats:table><\/jats:table-wrap><\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s10067-021-05839-9","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T07:04:01Z","timestamp":1626851041000},"page":"4933-4942","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Work absenteeism and disability associated with psoriasis and psoriatic arthritis in the USA\u2014a retrospective study of claims data from 2009 TO 2020"],"prefix":"10.1007","volume":"40","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8644-8567","authenticated-orcid":false,"given":"A. M.","family":"Orbai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. M.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Dennis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Villacorta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Peterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Mesana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. D.","family":"Chakravarty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"I.","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. S.","family":"Karyekar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Pacou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Walsh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"issue":"4","key":"5839_CR1","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1111\/j.1365-2133.2006.07405.x","volume":"155","author":"L Dubertret","year":"2006","unstructured":"Dubertret L, Mrowietz U, Ranki A, Van De Kerkhof P, Chimenti S, Lotti T, Sch\u00e4fer G, survey Ep (2006) European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 155(4):729\u2013736. https:\/\/doi.org\/10.1111\/j.1365-2133.2006.07405.x","journal-title":"Br J Dermatol"},{"issue":"3","key":"5839_CR2","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.jaad.2013.11.013","volume":"70","author":"TD Rachakonda","year":"2014","unstructured":"Rachakonda TD, Schupp CW, Armstrong AW (2014) Psoriasis prevalence among adults in the United States. J Am Acad Dermatol 70(3):512\u2013516. https:\/\/doi.org\/10.1016\/j.jaad.2013.11.013","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"5839_CR3","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1111\/j.1365-2133.1994.tb08454.x","volume":"131","author":"G Swanbeck","year":"1994","unstructured":"Swanbeck G, Inerot A, Martinsson T, Wahlstr\u00f6m J (1994) A population genetic study of psoriasis. Br J Dermatol 131(1):32\u201339. https:\/\/doi.org\/10.1111\/j.1365-2133.1994.tb08454.x","journal-title":"Br J Dermatol"},{"issue":"8","key":"5839_CR4","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/1346-8138.13806","volume":"44","author":"J Zeng","year":"2017","unstructured":"Zeng J, Luo S, Huang Y, Lu Q (2017) Critical role of environmental factors in the pathogenesis of psoriasis. J Dermatol 44(8):863\u2013872. https:\/\/doi.org\/10.1111\/1346-8138.13806","journal-title":"J Dermatol"},{"issue":"6","key":"5839_CR5","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/0190-9622(95)91336-x","volume":"32","author":"T Henseler","year":"1995","unstructured":"Henseler T, Christophers E (1995) Disease concomitance in psoriasis. J Am Acad Dermatol 32(6):982\u2013986. https:\/\/doi.org\/10.1016\/0190-9622(95)91336-x","journal-title":"J Am Acad Dermatol"},{"issue":"14","key":"5839_CR6","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1001\/jama.296.14.1735","volume":"296","author":"JM Gelfand","year":"2006","unstructured":"Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB (2006) Risk of myocardial infarction in patients with psoriasis. JAMA Dermatol 296(14):1735\u20131741. https:\/\/doi.org\/10.1001\/jama.296.14.1735","journal-title":"JAMA Dermatol"},{"issue":"2","key":"5839_CR7","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000062","volume":"2","author":"EJ Armstrong","year":"2013","unstructured":"Armstrong EJ, Harskamp CT, Armstrong AW (2013) Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc 2(2):e000062. https:\/\/doi.org\/10.1161\/JAHA.113.000062","journal-title":"J Am Heart Assoc"},{"issue":"5","key":"5839_CR8","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Gladman DD, Papp KA, Khraishi MM, Tha\u00e7i D, Behrens F, Northington R, Fuiman J, Bananis E, Boggs R (2013) Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol 69(5):729\u2013735. https:\/\/doi.org\/10.1016\/j.jaad.2013.07.023","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"5839_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jaad.2015.05.001","volume":"73","author":"AP Villani","year":"2015","unstructured":"Villani AP, Rouzaud M, Sevrain M, Barnetche T, Paul C, Richard M-A, Beylot-Barry M, Misery L, Joly P, Le Maitre M (2015) Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: systematic review and meta-analysis. J Am Acad Dermatol 73(2):242\u2013248. https:\/\/doi.org\/10.1016\/j.jaad.2015.05.001","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"5839_CR10","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1016\/j.jaad.2018.11.058","volume":"80","author":"CA Elmets","year":"2019","unstructured":"Elmets CA, Leonardi CL, Davis DM, Gelfand JM, Lichten J, Mehta NN, Armstrong AW, Connor C, Cordoro KM, Elewski BE (2019) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. J Am Acad Dermatol 80(4):1073\u20131113. https:\/\/doi.org\/10.1016\/j.jaad.2018.11.058","journal-title":"J Am Acad Dermatol"},{"key":"5839_CR11","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3899\/jrheum.090218","volume":"83","author":"I Olivieri","year":"2009","unstructured":"Olivieri I, Padula A, D\u2019Angelo S, Cutro MS (2009) Psoriatic arthritis sine psoriasis. J Rheumatol Suppl 83:28\u201329. https:\/\/doi.org\/10.3899\/jrheum.090218","journal-title":"J Rheumatol Suppl"},{"issue":"10","key":"5839_CR12","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD (2017) Psoriatic arthritis. N Engl J Med 376(10):957\u2013970. https:\/\/doi.org\/10.1056\/NEJMra1505557","journal-title":"N Engl J Med"},{"issue":"5","key":"5839_CR13","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1136\/ard.2008.089367","volume":"68","author":"V Chandran","year":"2009","unstructured":"Chandran V, Schentag CT, Brockbank JE, Pellett FJ, Shanmugarajah S, Toloza SM, Rahman P, Gladman DD (2009) Familial aggregation of psoriatic arthritis. Ann Rheum Dis 68(5):664\u2013667. https:\/\/doi.org\/10.1136\/ard.2008.089367","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"5839_CR14","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11926-015-0540-1","volume":"17","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Gelfand J (2015) Clinical risk factors for the development of psoriatic arthritis among patients with psoriasis: a review of available evidence. Curr Rheumatol Rep 17(10):64. https:\/\/doi.org\/10.1007\/s11926-015-0540-1","journal-title":"Curr Rheumatol Rep"},{"issue":"2","key":"5839_CR15","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1590\/S0365-05962013000200008","volume":"88","author":"VF Azevedo","year":"2013","unstructured":"Azevedo VF, Buiar PG (2013) Risk factors and predictors of psoriatic arthritis in patients with psoriasis. An Bras Dermatol 88(2):233\u2013236. https:\/\/doi.org\/10.1590\/S0365-05962013000200008","journal-title":"An Bras Dermatol"},{"issue":"5","key":"5839_CR16","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2174\/1570161117666190426164306","volume":"18","author":"C Papagoras","year":"2020","unstructured":"Papagoras C, Voulgari PV, Drosos AA (2020) Cardiovascular disease in spondyloarthritides. Curr Vasc Pharmacol 18(5):473\u2013487. https:\/\/doi.org\/10.2174\/1570161117666190426164306","journal-title":"Curr Vasc Pharmacol"},{"issue":"2","key":"5839_CR17","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1684\/ejd.2011.1635","volume":"22","author":"O Ghatnekar","year":"2012","unstructured":"Ghatnekar O, Ljungberg A, Wirestrand L-E, Svensson \u00c5 (2012) Costs and quality of life for psoriatic patients at different degrees of severity in southern Sweden\u2013a cross-sectional study. Eur J Dermatol 22(2):238\u2013245. https:\/\/doi.org\/10.1684\/ejd.2011.1635","journal-title":"Eur J Dermatol"},{"issue":"2","key":"5839_CR18","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1159\/000090654","volume":"212","author":"S Sohn","year":"2006","unstructured":"Sohn S, Sch\u00f6ffski O, Prinz J, Reich K, Schubert E, Waldorf K, Augustin M (2006) Cost of moderate to severe plaque psoriasis in Germany: a multicenter cost-of-illness study. Dermatology 212(2):137\u2013144. https:\/\/doi.org\/10.1159\/000090654","journal-title":"Dermatology"},{"issue":"2","key":"5839_CR19","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2147\/tcrm.s2740","volume":"4","author":"GL Colombo","year":"2008","unstructured":"Colombo GL, Altomare G, Peris K, Martini P, Quarta G, Congedo M, Costanzo A, Di Cesare A, Lapucci E, Chimenti S (2008) Moderate and severe plaque psoriasis: cost-of-illness study in Italy. Ther Clin Risk Manag 4(2):559. https:\/\/doi.org\/10.2147\/tcrm.s2740","journal-title":"Ther Clin Risk Manag"},{"issue":"6","key":"5839_CR20","doi-asserted-by":"publisher","first-page":"684","DOI":"10.2340\/00015555-1591","volume":"93","author":"M Ekelund","year":"2013","unstructured":"Ekelund M, Mallbris L, Qvitzau S, Stenberg B (2013) A higher score on the dermatology life quality index, being on systemic treatment and having a diagnosis of psoriatic arthritis is associated with increased costs in patients with plaque psoriasis. Acta Derm Venereol 93(6):684\u2013688. https:\/\/doi.org\/10.2340\/00015555-1591","journal-title":"Acta Derm Venereol"},{"issue":"5","key":"5839_CR21","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/j.jaad.2008.06.043","volume":"59","author":"JF Fowler","year":"2008","unstructured":"Fowler JF, Duh MS, Rovba L, Buteau S, Pinheiro L, Lobo F, Sung J, Doyle JJ, Swensen A, Mallett DA (2008) The impact of psoriasis on health care costs and patient work loss. J Am Acad Dermatol 59(5):772\u2013780. https:\/\/doi.org\/10.1016\/j.jaad.2008.06.043","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"5839_CR22","doi-asserted-by":"publisher","first-page":"640","DOI":"10.3899\/jrheum.150406","volume":"43","author":"S L\u00f6fvendahl","year":"2016","unstructured":"L\u00f6fvendahl S, Petersson IF, Theander E, Svensson \u00c5, Zhou C, Carlsson KS (2016) Incremental costs for psoriasis and psoriatic arthritis in a population-based cohort in Southern Sweden: is it all psoriasis-attributable morbidity? J Rheumatol 43(3):640\u2013647. https:\/\/doi.org\/10.3899\/jrheum.150406","journal-title":"J Rheumatol"},{"issue":"5","key":"5839_CR23","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1136\/ard.2008.092049","volume":"68","author":"M Wallenius","year":"2009","unstructured":"Wallenius M, Skomsvoll J, Koldingsnes W, R\u00f8devand E, Mikkelsen K, Kaufmann C, Kvien TK (2009) Work disability and health-related quality of life in males and females with psoriatic arthritis. Ann Rheum Dis 68(5):685\u2013689. https:\/\/doi.org\/10.1136\/ard.2008.092049","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"5839_CR24","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1093\/rheumatology\/keq131","volume":"49","author":"SM Verstappen","year":"2010","unstructured":"Verstappen SM, Watson KD, Lunt M, McGrother K, Symmons DP, Hyrich KL (2010) Working status in patients with rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis: results from the British Society for Rheumatology Biologics Register. Rheumatology 49(8):1570\u20131577. https:\/\/doi.org\/10.1093\/rheumatology\/keq131","journal-title":"Rheumatology"},{"issue":"5","key":"5839_CR25","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1111\/j.1468-3083.2009.03463.x","volume":"24","author":"E Christophers","year":"2010","unstructured":"Christophers E, Barker J, Griffiths C, Dauden E, Milligan G, Molta C, Sato R, Boggs R (2010) The risk of psoriatic arthritis remains constant following initial diagnosis of psoriasis among patients seen in European dermatology clinics. J Eur Acad Dermatol Venereol 24(5):548\u2013554. https:\/\/doi.org\/10.1111\/j.1468-3083.2009.03463.x","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"5839_CR26","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.vhri.2014.07.008","volume":"4","author":"K Kruntor\u00e1dov\u00e1","year":"2014","unstructured":"Kruntor\u00e1dov\u00e1 K, Klime\u0161 J, \u0160edov\u00e1 L, \u0160tolfa J, Dole\u017eal T, Pet\u0159\u00edkov\u00e1 A (2014) Work productivity and costs related to patients with ankylosing spondylitis, rheumatoid arthritis, and psoriasis. Value Health Reg Issues 4:100\u2013106. https:\/\/doi.org\/10.1016\/j.vhri.2014.07.008","journal-title":"Value Health Reg Issues"},{"issue":"8","key":"5839_CR27","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.3899\/jrheum.140259","volume":"41","author":"JA Walsh","year":"2014","unstructured":"Walsh JA, McFadden ML, Morgan MD, Sawitzke AD, Duffin KC, Krueger GG, Clegg DO (2014) Work productivity loss and fatigue in psoriatic arthritis. J Rheumatol 41(8):1670\u20131674. https:\/\/doi.org\/10.3899\/jrheum.140259","journal-title":"J Rheumatol"},{"issue":"2","key":"5839_CR28","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1080\/13696998.2018.1557201","volume":"22","author":"D Pilon","year":"2019","unstructured":"Pilon D, Teeple A, Zhdanava M, Ladouceur M, Ching Cheung H, Muser E, Lefebvre P (2019) The economic burden of psoriasis with high comorbidity among privately insured patients in the United States. J Med Econ 22(2):196\u2013203. https:\/\/doi.org\/10.1080\/13696998.2018.1557201","journal-title":"J Med Econ"},{"issue":"9","key":"5839_CR29","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s00296-016-3514-3","volume":"36","author":"P Kawalec","year":"2016","unstructured":"Kawalec P, Malinowski K, Pilc A (2016) Disease activity, quality of life and indirect costs of psoriatic arthritis in Poland. Rheumatol Int 36(9):1223\u20131230. https:\/\/doi.org\/10.1007\/s00296-016-3514-3","journal-title":"Rheumatol Int"},{"issue":"1","key":"5839_CR30","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s12913-015-0752-0","volume":"15","author":"A Mustonen","year":"2015","unstructured":"Mustonen A, Mattila K, Leino M, Koulu L, Tuominen R (2015) How much of the productivity losses among psoriasis patients are due to psoriasis. BMC Health Serv Res 15(1):87. https:\/\/doi.org\/10.1186\/s12913-015-0752-0","journal-title":"BMC Health Serv Res"},{"issue":"12","key":"5839_CR31","doi-asserted-by":"publisher","first-page":"2955","DOI":"10.1038\/jid.2015.296","volume":"135","author":"J Takeshita","year":"2015","unstructured":"Takeshita J, Gelfand JM, Li P, Pinto L, Yu X, Rao P, Viswanathan HN, Doshi JA (2015) Psoriasis in the US Medicare population: prevalence, treatment, and factors associated with biologic use. J Investig Dermatol 135(12):2955\u20132963","journal-title":"J Investig Dermatol"},{"issue":"5","key":"5839_CR32","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","volume":"40","author":"M Charlson","year":"1987","unstructured":"Charlson M, Pompei P, Ales K, MacKenzie C (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chron Dis 40(5):373\u2013383. https:\/\/doi.org\/10.1016\/0021-9681(87)90171-8","journal-title":"J Chron Dis"},{"issue":"10","key":"5839_CR33","doi-asserted-by":"publisher","first-page":"2751","DOI":"10.1007\/s10067-018-4187-y","volume":"37","author":"J Merola","year":"2018","unstructured":"Merola J, Herrera V, Palmer J (2018) Direct healthcare costs and comorbidity burden among patients with psoriatic arthritis in the USA. Clin Rheumatol 37(10):2751\u20132761. https:\/\/doi.org\/10.1007\/s10067-018-4187-y","journal-title":"Clin Rheumatol"},{"issue":"5","key":"5839_CR34","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1002\/acr.22492","volume":"67","author":"S Feldman","year":"2015","unstructured":"Feldman S, Zhao Y, Shi L, Tran M, Lu J (2015) Economic and comorbidity burden among moderate-to-severe psoriasis patients with comorbid psoriatic arthritis. Arthritis Care Res 67(5):708\u2013717. https:\/\/doi.org\/10.1002\/acr.22492","journal-title":"Arthritis Care Res"},{"key":"5839_CR35","unstructured":"U.S. Bureau of Labor Statistics Average Hourly Earnings of All Employees: Total Private. https:\/\/fred.stlouisfed.org\/series\/CES0500000003. Accessed July 24th 2020"},{"key":"5839_CR36","unstructured":"U.S. Bureau of Labor Statistics CPI-All Urban Consumers (Current Series). https:\/\/www.bls.gov\/cpi\/data.htm. Accessed July 24th 2020"},{"key":"5839_CR37","unstructured":"U.S. Bureau of Labor Statistics (2020) National Compensation Survey: glossary of employee benefit terms. https:\/\/www.bls.gov\/ncs\/ebs\/national-compensation-survey-glossary-of-employee-benefit-terms.htm. Accessed April 28th 2021"},{"key":"5839_CR38","unstructured":"Monaco K (2015) Disability insurance plans: trends in employee access and employer costs. U.S. Bureau of Labor Statistics.\u00a0https:\/\/www.bls.gov\/opub\/btn\/volume-4\/disability-insurance-plans.htm.\u00a0Accessed 28 Apr\u00a02021"},{"key":"5839_CR39","unstructured":"U.S. Bureau of Labor Statistics (2013) Short-term disability plans: Fixed percent of annual earnings. https:\/\/www.bls.gov\/ncs\/ebs\/benefits\/2013\/ownership\/private\/table36a.htm. Accessed April 28th 2021"},{"issue":"3","key":"5839_CR40","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1097\/JOM.0b013e318282d310","volume":"55","author":"NL Kleinman","year":"2013","unstructured":"Kleinman NL, Cifaldi MA, Smeeding JE, Shaw JW, Brook RA (2013) Annual incremental health benefit costs and absenteeism among employees with and without rheumatoid arthritis. J Occup Environ Med 55(3):240\u2013244. https:\/\/doi.org\/10.1097\/JOM.0b013e318282d310","journal-title":"J Occup Environ Med"},{"issue":"2","key":"5839_CR41","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1586\/14737167.2015.1001370","volume":"15","author":"KP Malinowski","year":"2015","unstructured":"Malinowski KP, Kawalec P (2015) The indirect costs of ankylosing spondylitis: a systematic review and meta-analysis. Expert Rev Pharmacoecon Outcomes Res 15(2):285\u2013300. https:\/\/doi.org\/10.1586\/14737167.2015.1001370","journal-title":"Expert Rev Pharmacoecon Outcomes Res"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05839-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-021-05839-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-021-05839-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,18]],"date-time":"2021-11-18T01:04:42Z","timestamp":1637197482000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-021-05839-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":41,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5839"],"URL":"https:\/\/doi.org\/10.1007\/s10067-021-05839-9","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"28 January 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"AMO was a PI on research grants to Johns Hopkins University from Abbvie, Amgen, Celgene, Eli Lilly, and Novartis, and a paid consultant for Eli Lilly, Janssen, Novartis, Pfizer, and UCB. IL, YW and RV are employees of Janssen Pharmaceutical companies that manufacture products indicated for psoriasis and PsA. SDC, SP, and CSK are employees of Janssen Scientific Affairs, LLC and shareholders of Johnson & Johnson, of which Janssen Scientific Affairs, LLC is a wholly owned subsidiary. JW has grant support from AbbVie, Pfizer, and Merck, and has served as a consultant for AbbVie, Amgen, Janssen, Lilly, Novartis, Pfizer, and UCB. SMR, ND, LM, and MP have no conflicts to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}